Header
AveXis is now Novartis Gene Therapies. Novartis Gene Therapies is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases.
6

Projects in Novartis Gene Therapies pipeline

162

Projects in our clinical pipeline

Novartis Clinical Pipeline

Newborn screening for SMA

In its most severe forms, spinal muscular atrophy can progress rapidly. Early diagnosis through newborn screening can help detect the disease before symptoms appear to aid early treatment intervention.

Learn More

 


Novartis Gene Therapies Grants

Novartis Gene Therapies wants to ensure that physicians, researchers, and other healthcare professionals have access to complete, up-to-date, and balanced scientific information regarding gene therapy treatment, research and investigational therapies.

Learn More

Contact Novartis Gene Therapies

Please direct any of your medical inquiries to the Novartis Gene Therapies MedInfo team in the USEuropeMiddle East and AsiaLatin America & Canada, or Asia-Pacific.

Side effects of Novartis medicines can be reported online or to local Novartis Drug Safety Responsible at report.novartis.com.